These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 591982

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD.
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO, von Kummer R, Eckert W, Weicker H.
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK, Mondal KN.
    Pharmatherapeutica; 1986 Feb; 4(9):571-6. PubMed ID: 3094036
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
    Jensen NO, Dupont E, Hansen E, Mikkelsen B, Mikkelsen BO.
    Eur Neurol; 1987 Feb; 27 Suppl 1():68-72. PubMed ID: 3428310
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F, Mentasti M, Riederer P, Birkmayer W.
    Wien Klin Wochenschr; 1979 May 11; 91(10):332-7. PubMed ID: 452602
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH, Lees AJ, Stern GM.
    Eur Neurol; 1987 May 11; 27 Suppl 1():93-7. PubMed ID: 3322842
    [Abstract] [Full Text] [Related]

  • 16. Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
    Barbeau A, Roy M.
    Neurology; 1976 May 11; 26(5):399-404. PubMed ID: 944392
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
    Birkmayer W, Birkmayer GD.
    J Neural Transm Suppl; 1986 May 11; 22():219-25. PubMed ID: 3097256
    [Abstract] [Full Text] [Related]

  • 19. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
    Lees AJ.
    Eur Neurol; 1987 May 11; 27 Suppl 1():126-34. PubMed ID: 3428306
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.